Aeglea BioTherapeutics (AGLE) P/E Ratio
P/E Ratio as of Jun 13, 2025: -5.70
Average-5.28
Median-5.07
Minimum-6.12
Maximum-4.79
-5.70
Past Month-0.82 (16.80%)
The P/E ratio for Aeglea BioTherapeutics (AGLE) is -5.70 as of Jun 13, 2025. This represents a increase of 223.86% compared to its 12-month average P/E ratio of -1.76. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Aeglea BioTherapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Aeglea BioTherapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Aeglea BioTherapeutics to industry peers.
Aeglea BioTherapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Aeglea BioTherapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Aeglea BioTherapeutics to industry peers.
Aeglea BioTherapeutics (AGLE) P/E Ratio Insights
See Aeglea BioTherapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Aeglea BioTherapeutics (AGLE)
Order type
Buy in
Order amount
Est. shares
0 shares
Aeglea BioTherapeutics (AGLE) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jun 2, 2025 | $15.40 | -5.07 |
| May 1, 2025 | $14.66 | -4.64 |
| Apr 1, 2025 | $15.295 | -4.84 |
| Mar 3, 2025 | $17.94 | -5.68 |
| Feb 3, 2025 | $22.90 | 2.49 |
| Jan 2, 2025 | $23.85 | 2.59 |
Aeglea BioTherapeutics (AGLE) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -5.70 | -325.30% |
| 2024 | 2.53 | -1,003.57% |
| 2023 | -0.28 | -22.22% |
| 2022 | -0.36 | -91.63% |
| 2021 | -4.30 | -5.29% |
| 2020 | -4.54 | — |
FAQs About Aeglea BioTherapeutics (AGLE) P/E ratio
The latest P/E ratio of Aeglea BioTherapeutics (AGLE) is -5.70, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Aeglea BioTherapeutics’s last 12-month average P/E ratio is -1.76, compared to its current P/E ratio of -5.70. This reflects a increase of 223.86%.
Aeglea BioTherapeutics’s current P/E ratio of -5.70 is higher than its last 12-month average P/E of -1.76. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Aeglea BioTherapeutics’s average P/E ratio over the last 3 years is -0.81. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Aeglea BioTherapeutics’s average P/E ratio over the last 5 years is -2.21. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.